Immunotherapy of kidney cancer. Where do the T lymphocytes go in kidney cancer?

我们研究的目的：-将由IHC检测一组肾癌中(CD4+AP/CD8+DAB)、CD103 DAB、CD39 DAB的表达-图像采集将使用蔡司扫描仪，并将使用QuPath 0.2.0-M8软件对每个样本上的上皮、肿瘤和间质区域进行注释。肿瘤区不包括坏死区、血细胞、血管。-通过颜色去卷积和阈值调整来检测其中的阳性免疫细胞。-阳性细胞检测通过光密度和来测量，并创建测量地图。-每mm_2的检测次数、阳性和阴性、阳性细胞百分比和Pf阳性细胞数将用于我们的分析。-聚类图将在一些样本中进行评估，以确定是否存在与肿瘤相关的阳性免疫细胞的特定模式。-将分析CD103和CD39细胞在肿瘤和良性上皮之间的位置，临床和病理数据将与我们的结果相关联。

Aims of our study: - Expression of (CD4+ AP/ CD8+ DAB), CD103 DAB, CD39 DAB will be determine by IHC in a group of renal cell carcinomas - Images acquisition will be done using a Zeiss scanner and epithelial, tumor and stroma areas will be annotated on each sample using the QuPath 0.2.0-m8 software. Areas of necrosis, blood cells, blood vessels were excluded from the tumor areas. - Positive immune cells within will be detected by color deconvolution and threshold adjustments. - Positive cell detection was measure by optical density sum, and measurements maps created. - Number of detections, positive ad negative, percentage of positive cells and number pf positive cells per mm_2 will be recorded for our analysis. - Cluster maps will be evaluated in some samples to determine the presence or not of a specific pattern of positive immune cell in relation with tumor ones. - The CD103 and CD39 cells location will be analyzed between tumor and benign epithelium and clinical and pathological data will be correlated with our results.